These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17656601)

  • 1. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.
    Frank-Raue K; Fabel M; Delorme S; Haberkorn U; Raue F
    Eur J Endocrinol; 2007 Aug; 157(2):215-20. PubMed ID: 17656601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.
    de Groot JW; Zonnenberg BA; van Ufford-Mannesse PQ; de Vries MM; Links TP; Lips CJ; Voest EE
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3466-9. PubMed ID: 17579194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
    Ha HT; Lee JS; Urba S; Koenig RJ; Sisson J; Giordano T; Worden FP
    Thyroid; 2010 Sep; 20(9):975-80. PubMed ID: 20718683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: "Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors".
    Plaza Menacho I; de Groot JW; Links T; Plukker J; Eggen BJ; Hofstra R
    Surgery; 2004 Feb; 135(2):240-1; author reply 241. PubMed ID: 14760839
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
    N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
    Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
    Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
    J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
    Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
    Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
    Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET signals through focal adhesion kinase in medullary thyroid cancer cells.
    Panta GR; Nwariaku F; Kim LT
    Surgery; 2004 Dec; 136(6):1212-7. PubMed ID: 15657578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
    J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
    van Oosterom AT; Judson I; Verweij J; Stroobants S; Donato di Paola E; Dimitrijevic S; Martens M; Webb A; Sciot R; Van Glabbeke M; Silberman S; Nielsen OS;
    Lancet; 2001 Oct; 358(9291):1421-3. PubMed ID: 11705489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
    Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
    Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
    Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
    Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
    Raccah E; Merimsky O; Kuten A; Apter S; Catane R
    Harefuah; 2007 May; 146(5):329-34, 408. PubMed ID: 17674545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.